ARCADIA,
Calif., May 7, 2024 /PRNewswire/ -- Theragent
Inc., a comprehensive CDMO focused on advancing next-generation
cell- and tissue-based therapies, has announced a partnership with
Pluristyx, Inc., an early stage, privately held biotechnology
company specializing in induced Pluripotent Stem Cell (iPSC)
products. Combined, this partnership will allow the companies to
provide a seamless, end-to-end pathway to therapeutics developers
from iPSC derivation to commercial production of iPSC-derived drug
products.
Under the terms of the collaboration, Pluristyx's iPSC platform,
including licenses for iPSC derivation, consent for use, and novel
mechanisms such as the FailSafe® functional suicide
switch and iACT Stealth Cells® immune evasion
technology, will be utilized for early-stage programs and then
synchronously transferred to Theragent for GMP processing including
scale-up and clinical- to commercial-scale production at their
state-of-the-art manufacturing facility in Arcadia, CA.
"Pluristyx is eager to grow our relationship with Theragent to
create a synchronized platform that combines our clinical-grade
iPSC lines and their CGMP manufacturing capabilities," said Dr.
Benjamin Fryer, CEO and Co-founder
of Pluristyx. "Together, we're able to create a streamlined and
transparent path from the bench to commercialization for the
next-generation of iPSC-derived treatments."
"iPSC's show untapped therapeutic potential, making it natural
to enter a preferred partnership with an iPSC technical authority
like Pluristyx," said Dr. Yu Yen,
MD, PhD, and CEO of Theragent. "The tie-up leverages our stem
cell expertise and our modern Pharma 4.0-driven manufacturing
facility, resulting in 'right first time, on time' tech transfer
and production – saving clients time and money while de-risking
their clinical program."
About Theragent
Theragent is an advanced therapeutics Contract Development
Manufacturing Organization in Arcadia,
CA focused on accelerating scientifically complex cell- and
tissue-based therapies for the treatment of cancer and other
diseases with unmet medical needs. The company's innovative cGMP
facility offers comprehensive end-to-end manufacturing and in-house
testing capabilities for clinical and commercial purposes. With a
skilled scientific team and an emphasis on quality, safety, and
next-gen manufacturing, Theragent strives to provide value-added
solutions for clients with challenging pre-clinical and clinical
trial projects.
Theragent. Patients are waiting. For more information, visit
www.theragent.com.
About Pluristyx
Pluristyx, through its panCELLa platform, offers a portfolio of
unique iPSC-based technologies, proprietary genetic engineering,
and related tool-products and services to provide end-to-end client
support throughout the products' lifecycle. Pluristyx is fast
becoming the leading provider of gene-edited iPSC and cell therapy
solutions, accelerating customers' path to clinic, and providing
the best and fastest route to commercialization for cell-based
therapeutic products. For more information on Pluristyx, visit
www.pluristyx.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/theragent-and-pluristyx-enter-partnership-to-streamline-and-advance-ipsc-derived-therapy-development-302136448.html
SOURCE Theragent